Provided by Tiger Trade Technology Pte. Ltd.

Johnson & Johnson

239.93
+4.661.98%
Post-market: 239.92-0.01000.00%19:55 EDT
Volume:6.46M
Turnover:1.55B
Market Cap:578.06B
PE:21.75
High:241.46
Open:236.80
Low:235.73
Close:235.27
52wk High:251.71
52wk Low:141.50
Shares:2.41B
Float Shares:2.40B
Volume Ratio:0.67
T/O Rate:0.27%
Dividend:5.14
Dividend Rate:2.14%
EPS(TTM):11.03
EPS(LYR):11.03
ROE:35.03%
ROA:8.68%
PB:7.09
PE(LYR):21.75

Loading ...

Zymeworks Publishes Corporate Presentation on Royalty-Driven Growth Strategy and Oncology Pipeline Progress

Reuters
·
Mar 02

United Therapeutics' drug slows progression of rare lung condition in late-stage study

Reuters
·
Mar 02

Boeing, Walmart, Coca-Cola, Ford, J&J: Insider Moves Exposed

TIPRANKS
·
Feb 28

Perrigo Co. PLC Stock Underperforms Thursday When Compared To Competitors

Dow Jones
·
Feb 27

Johnson & Johnson reports promising Phase 1b pasritamig plus docetaxel results in advanced prostate cancer

Reuters
·
Feb 27

J&J: Combination Demonstrates Deep Psa Responses and Favorable Safety Profile With Plans to Advance Into Phase 3

THOMSON REUTERS
·
Feb 27

Early Study Results From Johnson & Johnson Show Promising Antitumor Activity With Combination of Pasritamig and Docetaxel in Advanced Prostate Cancer

THOMSON REUTERS
·
Feb 27

J&J: Combination Demonstrated a Safety Profile Consistent With Docetaxel Alone, With No New or Unexpected Safety Signals Observed

THOMSON REUTERS
·
Feb 27

Judge Rejects Kenvue Bid to Dismiss Texas Attorney General's Lawsuit Over Marketing of Tylenol, Court Order Shows

THOMSON REUTERS
·
Feb 27

Judge rejects Kenvue bid to dismiss Texas lawsuit over Tylenol

Reuters
·
Feb 27

Johnson & Johnson Completes Catheter Portfolio With Launch of Cereglide™ 42, Cereglide™ 57, and Innerglide™ 7

THOMSON REUTERS
·
Feb 26

DBS Remains a Hold on Johnson & Johnson (JNJ)

TIPRANKS
·
Feb 25

How JNJ, TEM, and LLY Used AI to Redefine Healthcare Compounding

TIPRANKS
·
Feb 25

Johnson & Johnson submits sBLA to FDA for approval of Imaavy

TIPRANKS
·
Feb 25

Johnson & Johnson seeks FDA approval for IMAAVY in warm autoimmune hemolytic anemia

Reuters
·
Feb 25

Johnson & Johnson Seeks FDA Approval of Imaavy® (Nipocalimab-Aahu) as the First-Ever FDA-Approved Treatment for Warm Autoimmune Hemolytic Anemia (Waiha)

THOMSON REUTERS
·
Feb 25

Option Movers | PayPal's $50 Call Soars 1700%; Novo Nordisk's $40 Put Surges 1192%; J&J Sees 98% Call Options

Option Movers
·
Feb 24

Perrigo Co. PLC Stock Underperforms Monday When Compared To Competitors

Dow Jones
·
Feb 24

Johnson & Johnson EVP, WW Chair, MedTech Timothy Schmid Disposes of Common Shares

Reuters
·
Feb 24

BRIEF-Johnson & Johnson Announces Approval Of Subcutaneous Rybrevant®▼ By European Commission

Reuters
·
Feb 24